Association Between Drug-Eluting Stent Type and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Chan, William K.; Ivanov, Joan; Kotowycz, Mark A.; Sibbald, Matthew; McGeoch, Ross; Crooks, Noel; Hatton, Rachael; Ing, Douglas; Daly, Paul; Mackie, Karen; Osten, Mark; Seidelin, Peter H.; Barolet, Alan; Overgaard, Christopher B.; Džavík, Vladimir

doi:10.1016/j.cjca.2014.04.034

Cited by 15 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that the use of new-generation DES (everolimus-, zotarolimus-, and biolimus-eluting stents) in CKD patients does not attenuate the high risk of MACCE and death at the 1-year follow-up. This finding echoes Chan et al [27] who compared DES-I and DES-II in CKD, but in a 2-year follow-up. As in our study, they did not observe any significant difference in terms of safety and efficacy between the 2 generations of DES.…”

Section: Discussionsupporting

confidence: 83%

Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents

et al. 2016

View full text Add to dashboard Cite

Background: The following registry (Katowice-Zabrze retrospective registry) aimed to assess the influence of a chronic kidney disease (CKD) on long-term clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) using either first-generation (DES-I) or second-generation (DES-II) drug-eluting stents. Methods: The study group consisted of 1,908 consecutive patients, of whom 331 (17.3%) had CKD. CKD was defined as an estimated glomerular filtration rate of <60 mL/min/m². We evaluated the major adverse cardiac and cerebral events (MACCE), i.e., the composite of death, myocardial infarction (MI), stroke, and target vessel revascularization at the 12-month follow-up. Results: CKD patients had a lower left ventricular ejection fraction and more often a history of MI and PCI. Coronary angiography revealed that multivessel coronary artery disease, intracoronary thrombus, and extensive calcifications were more frequent in patients with CKD. However, the SYNTAX score did not vary between patients with or without CKD. There was a higher rate of in-hospital bleedings requiring blood transfusion in patients with CKD. At the 1-year follow-up, MACCE (17.8 vs. 12.6%, HR = 1.46 [95% CI 1.05-2.03], p = 0.009) and death (8.4 vs. 2.3%, HR = 3.9 [95% CI 2.0-7.5], p < 0.001) were more often observed in CKD patients. Multivariable Cox analysis revealed that CKD was an independent risk predictor of death after PCI at the 1-year follow-up (HR = 2.1 [95% CI 1.2-3.6], p = 0.004). In comparison to DES-I, the use of DES-II did not decrease the adverse effect of CKD on MACCE. Conclusion: CKD patients had an increased risk of in-hospital bleeding requiring blood transfusion and a higher risk of MACCE and death at the 12-month follow-up. The use of second-generation DES did not improve clinical outcomes in patients with CKD at the 12-month follow-up.

show abstract

Section: Discussionsupporting

confidence: 83%

Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents

et al. 2016

View full text Add to dashboard Cite

show abstract

“…All patients undergoing PCI at the Peter Munk Cardiac Centre, University Health Network (Toronto, Canada) are enrolled into a dedicated prospective registry . This database was used to identify all patients who underwent PCI within 1 year of CABG at Toronto General Hospital, between April 1, 2000 and June 30, 2011.…”

Section: Methodsmentioning

confidence: 99%

Characteristics and outcomes of patients undergoing percutaneous coronary intervention within 1 year of coronary artery bypass graft surgery

Sharma

Kotowycz

Sharma

et al. 2017

Cathet Cardio Intervent

Self Cite

View full text Add to dashboard Cite

Patients who required PCI within 1 year of CABG were more likely to present on an urgent basis and have PCI performed in grafted native coronary vessels. However, nearly third of the patients had PCI to an ungrafted native vessel or to a lesion in the native vessel where the graft was still patent. Further studies are needed to determine whether the use of hybrid revascularization strategies (combination CABG and planned PCI) in appropriate patients could reduce the need for urgent PCI within the first year after CABG. © 2017 Wiley Periodicals, Inc.

show abstract

“…Demographic and procedural data were collected from the prospective data registry maintained at our institution . Indications for GuideLiner use, angiographic and procedural details including procedural success, and all complications were recorded prospectively.…”

Section: Methodsmentioning

confidence: 99%

“…Device success with the GuideLiner was defined as ability to deliver balloons or stents to the desired position during the procedure. Routine peri‐procedural creatine kinase was measured up to 24 hours after PCI. PCI related MI was defined as 3 times the upper reference limit of CK.…”

Section: Methodsmentioning

confidence: 99%

Efficacy and Safety of the GuideLiner Mother‐in‐Child Guide Catheter Extension in Percutaneous Coronary Intervention

Shah

Osten

et al. 2016

J Interven Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

Association Between Drug-Eluting Stent Type and Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Cited by 15 publications

References 30 publications

Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents

Long-Term Percutaneous Coronary Intervention Outcomes of Patients with Chronic Kidney Disease in the Era of Second-Generation Drug-Eluting Stents

Characteristics and outcomes of patients undergoing percutaneous coronary intervention within 1 year of coronary artery bypass graft surgery

Efficacy and Safety of the GuideLiner Mother‐in‐Child Guide Catheter Extension in Percutaneous Coronary Intervention

Contact Info

Product

Resources

About